Last Updated: August 2026
Published by: Saif Pharma — a specialist oncology medicine supplier serving patients, pharmacies, and distributors worldwide.
Medical Review: Reviewed by Dr. Nusrat Jahan, MBBS, MD (Medical Oncology)
Content Basis: This article is based on official prescribing information, product monographs, and regulatory product documentation from SFDA and DGDA (Directorate General of Drug Administration, Bangladesh).
Sources: en.wikipedia.org, skfbd.com, drugs.com, drugs.com, medex.com.bd, fda.gov

Key Takeaways
- Brigatinib is a tyrosine kinase inhibitor approved for adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), confirmed through an FDA-approved diagnostic test.
- It works by inhibiting ALK kinase activity along with ROS1, IGF-1R, and FLT-3, as well as EGFR deletion and point mutations, suppressing signaling that drives tumor growth.
- Bangladeshi-manufactured brigatinib is available under the brand names Bigatab, Trepmac, and Biganib, formulated as oral tablets in three strengths.
- Common side effects include diarrhea, fatigue, nausea, rash, and cough, while serious risks include interstitial lung disease/pneumonitis and hypertension, requiring ongoing clinical monitoring.
- Brigatinib is metabolized via the CYP3A4 pathway, making review of concomitant medications important before starting therapy.
- Bigatab, Trepmac, and Biganib are manufactured in Bangladesh and exported to Saudi Arabia in accordance with SFDA regulatory requirements.
What is Brigatinib Used For?
Brigatinib is an antineoplastic agent classified as a tyrosine kinase inhibitor (TKI). It is approved for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved diagnostic test. Identification of ALK rearrangement status is a prerequisite for therapy selection, and testing is performed using a validated companion diagnostic assay to confirm eligibility before treatment is considered.
NSCLC accounts for the majority of lung cancer cases, and a subset of patients harbor genetic rearrangements in the ALK gene that drive tumor growth. For these patients, targeted tyrosine kinase inhibition offers a treatment approach distinct from conventional cytotoxic chemotherapy, addressing the specific molecular driver of disease. Brigatinib belongs to this class of targeted agents developed for ALK-rearranged malignancies. This classification and mechanism align with the pharmacological description found in regulatory drug labels and peer-reviewed oncology literature on ALK-directed therapy.
As a B2B pharmaceutical supplier, our role is to ensure that healthcare institutions, pharmacies, and distributors in Saudi Arabia have access to Bangladeshi-manufactured brigatinib brands that meet the clinical needs of oncology treatment centers managing ALK-positive metastatic NSCLC. Our team tracks updates to product labeling and regulatory guidance for the brands we supply so that partner institutions can rely on current information when making procurement decisions. Related targeted therapies for other NSCLC molecular subtypes, such as EGFR-mutated disease, are addressed separately in our osimertinib resource for EGFR-mutated NSCLC, reflecting the broader landscape of biomarker-driven lung cancer therapy that procurement teams should be aware of.
How Brigatinib Works: Mechanism of Action
Brigatinib functions as a tyrosine kinase inhibitor with in vitro activity against multiple kinase targets. Its primary mechanism involves inhibition of ALK kinase activity, which suppresses the signaling pathways that drive proliferation in ALK-positive tumor cells. Beyond ALK, brigatinib demonstrates activity against ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3 kinases.
Brigatinib also inhibits EGFR deletion and point mutations in vitro. This broad kinase inhibition profile distinguishes its pharmacological activity from single-target agents and underlies its role in addressing ALK-driven NSCLC, including in patients whose disease has progressed following prior ALK-directed therapy. This multi-kinase inhibition profile forms the pharmacological basis for its clinical use in ALK-positive metastatic NSCLC.
These mechanistic details are consistent with published pharmacology data included in international prescribing information for brigatinib, and clinicians should refer to the official prescribing information for the complete pharmacodynamic and pharmacokinetic profile relevant to individual patient care.

Available Brands and Product Forms
As a Bangladeshi pharmaceutical supplier, we provide access to brigatinib under the locally manufactured brand names Bigatab, Trepmac, and Biganib. These formulations are produced to meet the therapeutic needs of oncology providers managing ALK-positive metastatic NSCLC across export markets, including Saudi Arabia.
Bigatab is manufactured by Eskayef Pharmaceuticals Ltd., a Bangladesh-based pharmaceutical manufacturer. Trepmac is produced by Genvio Pharma Ltd., also based in Bangladesh. Biganib is an additional Bangladeshi-manufactured brand available through our supply network. All three brands are formulated as oral tablets.
Brigatinib tablets are available in three strengths: 30 mg, 90 mg, and 180 mg. This range of strengths supports the dose titration schedules used in clinical practice, though specific regimens and strength selection must be determined by the treating physician in accordance with the official prescribing information. Tablets are intended to be swallowed whole and should not be crushed or chewed.
Procurement teams sourcing brigatinib for Saudi Arabian pharmacies and hospitals can request documentation on batch availability, strength configurations, and manufacturing details for Bigatab, Trepmac, and Biganib directly through our supplier network. We recommend that institutional buyers cross-check strength and packaging details against the manufacturer’s current product literature at the time of order confirmation.
Safety Profile: Side Effects and Precautions
Brigatinib therapy is associated with a defined profile of common and serious adverse effects that healthcare providers should monitor throughout treatment. Commonly reported reactions include diarrhea, fatigue, nausea, rash, and cough, among other effects.
Serious adverse effects requiring clinical vigilance include interstitial lung disease and pneumonitis, hypertension, bradycardia, visual disturbance, elevated creatine phosphokinase, elevated pancreatic enzymes, and hyperglycemia. Patients should be monitored for pulmonary symptoms, cardiovascular changes, and metabolic laboratory abnormalities during the course of therapy.
Brigatinib is primarily metabolized by CYP2C8 and CYP3A4 in vitro. This has implications for drug-drug interactions, as concomitant use of strong or moderate CYP3A inhibitors or inducers can alter brigatinib exposure. Prescribing physicians should review a patient’s full medication profile before initiating therapy to identify potential interactions along this metabolic pathway.
Regarding lactation, patients are advised not to breastfeed during treatment. All dosing decisions, including any adjustments related to hepatic or renal function or drug interactions, must be determined by the treating physician in accordance with the official prescribing information. This article does not provide dosing guidance; healthcare providers should consult full prescribing information for patient-specific management. The safety information summarized here reflects publicly available prescribing data and is intended to support procurement and clinical awareness, not to substitute for direct consultation of official regulatory labeling by treating physicians.

Regulatory Status in Saudi Arabia
Pharmaceutical products distributed in Saudi Arabia, including brigatinib formulations, are subject to the regulatory requirements administered by the Saudi Food and Drug Authority (SFDA, sfda.gov.sa). Importers, distributors, and healthcare institutions procuring brigatinib for the Saudi market must ensure compliance with applicable SFDA registration, labeling, and quality standards.
Internationally, brigatinib received initial FDA approval in 2017, with the prescribing label updated in 2020 to reflect additional clinical data. This regulatory history provides context for the drug’s established therapeutic profile, though SFDA requirements govern its specific import and distribution status within Saudi Arabia. The originator brand, Alunbrig, represents the internationally recognized reference product within this regulatory history.
It is important to clarify that our supplied brands—Bigatab, Trepmac, and Biganib—are manufactured in Bangladesh and exported to Saudi Arabia; they are not locally manufactured within the Kingdom. Our role as a supplier is to facilitate compliant export of these Bangladeshi-produced formulations to meet demand from Saudi healthcare institutions and distributors. We encourage procurement teams to verify current registration status of specific brands directly with SFDA or through their institutional regulatory affairs contacts prior to finalizing purchase agreements.
Why Source Brigatinib From Us
Sourcing brigatinib from an established Bangladeshi supplier offers procurement teams a dependable pathway to therapies for ALK-positive metastatic NSCLC. Bangladesh has developed a robust pharmaceutical manufacturing sector, with facilities such as Eskayef Pharmaceuticals Ltd. and Genvio Pharma Ltd. producing oncology formulations under structured quality and manufacturing standards.
Our organization has built export experience specifically oriented toward the Saudi Arabian market, understanding the documentation, compliance, and logistical requirements necessary to move pharmaceutical products from Bangladeshi manufacturing facilities to healthcare institutions and pharmacies within the Kingdom. This experience reduces friction for buyers navigating cross-border procurement of oncology medicines.
Quality assurance is maintained throughout our supply chain, from manufacturer verification through export documentation to final delivery coordination. For institutions seeking access to Bigatab, Trepmac, or Biganib, our supply relationships with Bangladeshi manufacturers provide a consistent channel for fulfilling brigatinib procurement needs while supporting compliance with destination market regulatory expectations. Our procurement specialists are available to walk purchasing teams through manufacturer credentials and quality documentation as part of the due-diligence process.
Our Ordering and Export Process
Our B2B ordering process begins with an initial inquiry from the purchasing institution, pharmacy, or distributor, during which we gather details on required brigatinib brand, strength, and quantity. This is followed by a documentation review stage, where necessary licensing, import permissions, and institutional credentials are verified to ensure the transaction meets both Bangladeshi export standards and Saudi Arabian import requirements.
Export compliance verification follows, confirming that shipments align with applicable regulatory frameworks, including documentation expected under SFDA oversight for pharmaceutical imports into Saudi Arabia. Our team coordinates with manufacturers such as Eskayef Pharmaceuticals Ltd. and Genvio Pharma Ltd. to confirm product availability and batch readiness.
Once compliance steps are finalized, we arrange shipping logistics for delivery to Saudi Arabia, coordinating with freight and customs processes suited to pharmaceutical cargo. Throughout this process, our team remains available to answer procurement questions. For specific availability, lead times, or pricing information on Bigatab, Trepmac, or Biganib, purchasing teams are encouraged to contact us directly.
Frequently Asked Questions
What is brigatinib used for?
Brigatinib is a targeted cancer therapy approved for adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), a diagnosis confirmed through an FDA-approved test that detects the ALK gene rearrangement.
Is brigatinib an ALK inhibitor?
Yes, brigatinib is a tyrosine kinase inhibitor that primarily works by blocking ALK kinase activity, which suppresses the signaling that drives growth in ALK-positive tumor cells.
What are the common side effects of brigatinib?
Commonly reported side effects include diarrhea, fatigue, nausea, rash, and cough, along with headache and increased blood pressure in some patients.
More serious effects such as interstitial lung disease, pneumonitis, and hypertension require close monitoring by a treating physician, so any new or worsening symptoms should be reported promptly.
Can brigatinib be taken by anyone with lung cancer?
No, brigatinib is specifically approved for adult patients whose NSCLC has been confirmed as ALK-positive through a validated diagnostic test, as it targets a specific genetic driver of tumor growth.
Which brigatinib brands are available for procurement in Saudi Arabia?
We supply Bangladeshi-manufactured brigatinib under the brand names Bigatab, Trepmac, and Biganib, produced by manufacturers including Eskayef Pharmaceuticals Ltd. and Genvio Pharma Ltd.
How does the export and ordering process work for institutions in Saudi Arabia?
The process begins with an inquiry covering brand, strength, and quantity, followed by documentation review to verify compliance with Bangladeshi export and Saudi Arabian import requirements.
Once export compliance is confirmed, shipping logistics are arranged for delivery to Saudi Arabia, with our team available throughout to answer procurement questions.
- 1. en.wikipedia.org — en.wikipedia.org
- 2. skfbd.com
- 3. www.drugs.com
- 4. drugs.com
- 5. medex.com.bd
- 6. www.fda.gov
Access This Medicine Through Saif Pharma
We are a specialist oncology medicine supplier delivering to patients, pharmacies, hospitals, and distributors worldwide. Contact us for availability and sourcing support.
We do not publish prices online. All pricing is provided directly by our specialist supply team on request.
Medical Information Notice: This content is for informational purposes only and is based on official pharmaceutical product documentation. It does not constitute medical advice. Patients should consult their doctor or pharmacist before taking any medication.
Regulatory Disclaimer: Sourcing and distribution are subject to regional import regulations, quotas, and verified medical prescriptions where applicable. Pricing and availability are subject to change without notice.
Content Currency: This article was last reviewed and updated in August 2026. Regulatory approval statuses and product availability are subject to change; readers are advised to consult official regulatory databases for the most current information.